vs
Side-by-side financial comparison of Currenc Group Inc. (CURR) and NewAmsterdam Pharma Co N.V. (NAMS). Click either name above to swap in a different company.
NewAmsterdam Pharma Co N.V. is the larger business by last-quarter revenue ($19.1M vs $10.1M, roughly 1.9× Currenc Group Inc.). Currenc Group Inc. runs the higher net margin — -46.5% vs -90.7%, a 44.2% gap on every dollar of revenue. On growth, NewAmsterdam Pharma Co N.V. posted the faster year-over-year revenue change (740.1% vs -23.3%). Currenc Group Inc. produced more free cash flow last quarter ($-1.7M vs $-37.8M).
Kite Pharma, Inc. is an American biotechnology company that develops cancer immunotherapy products with a primary focus on genetically engineered autologous CAR T cell therapy - a cell-based therapy which relies on chimeric antigen receptors and T cells. Founded in 2009, and based in Santa Monica, California, it was acquired by Gilead Sciences in 2017.
CURR vs NAMS — Head-to-Head
Income Statement — Q1 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $10.1M | $19.1M |
| Net Profit | $-4.7M | $-17.4M |
| Gross Margin | 31.8% | — |
| Operating Margin | -43.0% | -186.1% |
| Net Margin | -46.5% | -90.7% |
| Revenue YoY | -23.3% | 740.1% |
| Net Profit YoY | -54.0% | 55.5% |
| EPS (diluted) | $-0.13 | $-0.15 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | — | $19.1M | ||
| Q1 25 | $10.1M | — | ||
| Q4 24 | — | $12.8M | ||
| Q3 24 | $11.3M | $29.1M | ||
| Q1 24 | $13.1M | — | ||
| Q3 23 | $12.7M | — | ||
| Q2 23 | — | $8.6M |
| Q2 25 | — | $-17.4M | ||
| Q1 25 | $-4.7M | — | ||
| Q4 24 | — | $-92.2M | ||
| Q3 24 | $-5.0M | $-16.6M | ||
| Q1 24 | $-3.0M | — | ||
| Q3 23 | $-3.8M | — | ||
| Q2 23 | — | $-42.0M |
| Q2 25 | — | — | ||
| Q1 25 | 31.8% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 27.8% | — | ||
| Q1 24 | 33.6% | — | ||
| Q3 23 | 32.5% | — | ||
| Q2 23 | — | — |
| Q2 25 | — | -186.1% | ||
| Q1 25 | -43.0% | — | ||
| Q4 24 | — | -338.5% | ||
| Q3 24 | -141.5% | -85.9% | ||
| Q1 24 | -10.8% | — | ||
| Q3 23 | -18.2% | — | ||
| Q2 23 | — | -461.8% |
| Q2 25 | — | -90.7% | ||
| Q1 25 | -46.5% | — | ||
| Q4 24 | — | -721.7% | ||
| Q3 24 | -44.1% | -57.2% | ||
| Q1 24 | -23.2% | — | ||
| Q3 23 | -30.1% | — | ||
| Q2 23 | — | -486.9% |
| Q2 25 | — | $-0.15 | ||
| Q1 25 | $-0.13 | — | ||
| Q4 24 | — | $-0.91 | ||
| Q3 24 | $-0.13 | $-0.18 | ||
| Q1 24 | $-0.09 | — | ||
| Q3 23 | $-0.11 | — | ||
| Q2 23 | — | $-0.51 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $62.3M | $739.2M |
| Total DebtLower is stronger | $3.7M | — |
| Stockholders' EquityBook value | $-68.4M | $778.5M |
| Total Assets | $110.8M | $815.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $739.2M | ||
| Q1 25 | $62.3M | — | ||
| Q4 24 | — | $834.2M | ||
| Q3 24 | $49.1M | $422.7M | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q2 25 | — | — | ||
| Q1 25 | $3.7M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $20.1M | — | ||
| Q1 24 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | — |
| Q2 25 | — | $778.5M | ||
| Q1 25 | $-68.4M | — | ||
| Q4 24 | — | $757.5M | ||
| Q3 24 | $-47.0M | $378.9M | ||
| Q1 24 | $-10.9M | — | ||
| Q3 23 | $-10.2M | — | ||
| Q2 23 | — | $398.4M |
| Q2 25 | — | $815.1M | ||
| Q1 25 | $110.8M | — | ||
| Q4 24 | — | $864.6M | ||
| Q3 24 | $115.0M | $439.2M | ||
| Q1 24 | $54.5M | — | ||
| Q3 23 | $82.0M | — | ||
| Q2 23 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.5M | $-37.7M |
| Free Cash FlowOCF − Capex | $-1.7M | $-37.8M |
| FCF MarginFCF / Revenue | -16.5% | -197.2% |
| Capex IntensityCapex / Revenue | 1.7% | 0.5% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-119.7M |
8-quarter trend — quarters aligned by calendar period.
| Q2 25 | — | $-37.7M | ||
| Q1 25 | $-1.5M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | $-11.3M | $-12.5M | ||
| Q1 24 | $-221.0K | — | ||
| Q3 23 | $-10.5M | — | ||
| Q2 23 | — | $-31.9M |
| Q2 25 | — | $-37.8M | ||
| Q1 25 | $-1.7M | — | ||
| Q4 24 | — | $-37.5M | ||
| Q3 24 | — | $-12.6M | ||
| Q1 24 | $-233.0K | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | $-31.9M |
| Q2 25 | — | -197.2% | ||
| Q1 25 | -16.5% | — | ||
| Q4 24 | — | -293.5% | ||
| Q3 24 | — | -43.2% | ||
| Q1 24 | -1.8% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -369.3% |
| Q2 25 | — | 0.5% | ||
| Q1 25 | 1.7% | — | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.3% | ||
| Q1 24 | 0.1% | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 0.1% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CURR
| Sales Of Airtime | $5.5M | 54% |
| Fiat Remittance Service | $4.4M | 44% |
NAMS
Segment breakdown not available.
